10x Genomics (TXG) Projected to Announce Earnings on Thursday

10x Genomics (NASDAQ:TXG) is expected to be releasing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect 10x Genomics to post earnings of ($0.23) per share and revenue of $146.6740 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.19. The company had revenue of $150.84 million during the quarter, compared to analyst estimates of $146.41 million. 10x Genomics had a negative net margin of 3.55% and a negative return on equity of 2.86%. 10x Genomics’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter last year, the business posted ($0.28) EPS. On average, analysts expect 10x Genomics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

10x Genomics Trading Down 1.6%

NASDAQ:TXG opened at $46.32 on Thursday. 10x Genomics has a 12 month low of $11.16 and a 12 month high of $49.50. The firm’s 50 day moving average is $36.12 and its 200 day moving average is $26.32. The stock has a market capitalization of $5.88 billion, a PE ratio of -272.47 and a beta of 2.05.

Insider Buying and Selling at 10x Genomics

In related news, CEO Serge Saxonov sold 30,000 shares of 10x Genomics stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $34.44, for a total value of $1,033,200.00. Following the completion of the transaction, the chief executive officer directly owned 1,108,380 shares in the company, valued at approximately $38,172,607.20. The trade was a 2.64% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Adam Taich sold 15,098 shares of the business’s stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $24.44, for a total transaction of $368,995.12. Following the sale, the chief financial officer directly owned 379,898 shares in the company, valued at $9,284,707.12. The trade was a 3.82% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 91,309 shares of company stock valued at $2,581,357 over the last 90 days. 8.84% of the stock is currently owned by corporate insiders.

Institutional Trading of 10x Genomics

A number of institutional investors have recently added to or reduced their stakes in the stock. Cibc World Market Inc. boosted its stake in 10x Genomics by 2.2% in the 4th quarter. Cibc World Market Inc. now owns 63,849 shares of the company’s stock worth $1,041,000 after purchasing an additional 1,385 shares during the period. New York State Common Retirement Fund grew its holdings in 10x Genomics by 4.4% during the 4th quarter. New York State Common Retirement Fund now owns 36,017 shares of the company’s stock valued at $587,000 after buying an additional 1,533 shares in the last quarter. Creative Planning increased its position in shares of 10x Genomics by 3.0% during the third quarter. Creative Planning now owns 56,874 shares of the company’s stock valued at $665,000 after buying an additional 1,637 shares during the period. Van ECK Associates Corp lifted its holdings in shares of 10x Genomics by 85.9% in the fourth quarter. Van ECK Associates Corp now owns 3,668 shares of the company’s stock worth $60,000 after buying an additional 1,695 shares in the last quarter. Finally, Martingale Asset Management L P lifted its holdings in shares of 10x Genomics by 3.5% in the fourth quarter. Martingale Asset Management L P now owns 89,006 shares of the company’s stock worth $1,452,000 after buying an additional 3,003 shares in the last quarter. Hedge funds and other institutional investors own 84.68% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Citigroup raised their target price on 10x Genomics from $24.00 to $45.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 8th. Barclays upped their price target on 10x Genomics from $30.00 to $40.00 and gave the company an “overweight” rating in a research report on Wednesday, June 24th. Leerink Partners increased their price target on 10x Genomics from $23.00 to $40.00 and gave the stock a “market perform” rating in a research note on Friday, July 17th. Bank of America lifted their price objective on 10x Genomics from $21.00 to $30.00 and gave the stock a “neutral” rating in a report on Monday, April 20th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of 10x Genomics in a research note on Wednesday, June 24th. Four investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, 10x Genomics has a consensus rating of “Hold” and a consensus price target of $32.08.

About 10x Genomics

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.